Divi' s Laboratories Limited

@)

Date. ¹¹ d_f'~~ruary 2019

To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East) MUMBAI - 400 051

To The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street MUMBAI- 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/ Madam,

• Sub: Un-audited financial results for the quarter and nine months ended 31st December 2018 and limited review report -reg
• Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our letter dated 24¹ h January, 2019, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 2nd February 2019 has approved Un-audited Financial Results for the quarter and nine months ended 31st December, 2018.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

• 1. Un-audited Standalone Financial Results for the quarter and nine months ended 31st December, 2018.
• 1. Limited Review Report on the Standalone Financial Results
• 1. Press Release on the Financial Results of the Company

The Board meeting commenced at 11 :00 Hrs and concluded at 13:15 Hrs

This is for your information and records.

Thanking You,

Yours faithfully, For Divi's Laboratories Limited

~ ,() ,_,- r v L----

P V Lckshmi R~jani Company Secretary

"An IS0-9001, IS0-14001 and OHSAS-18001 Triple certified company"

Regd. Off.: Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad- 500 032, Telangana, INDIA. Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L2411 OTG1990PLC011854 E-mail : mail@ divislabs.com, Website : www.divislabs.com

DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 sT DECEMBER, 2018

(b ~~~ use Charterect <1 ~;.... u.PIM AAC.s0o1 ~~~ ~ .C·J ~;\ o>~o\t ~:;I~ ~~ r:t * Z27S4N/NSo00~ "" qr ~~ ^lliyderaba.d * ~ ~* ~

NOTES:

• I. The above results, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 2"d February, 2019.
• 1. Results for the quarter ended 31st December 2018 were subjected to 'limited review' by the Auditors and their report contains no qualification.
• 1. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per lnd AS I 08.
• 1. These financial results have been prepared in accordance with Indian Accounting Standards ('lnd AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
• 1. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end .
• 1. The Ministry of Corporate Affairs (MCA) on 281 ^hMarch 2018 notified lnd AS 115 "Revenue from contracts with customers" as part of the Companies (Indian Accounting Standards) Amendment Rules, 2018. The new Standard is effective for repotting periods beginning on or after 1'1 April2018. The adoption ofthe standard did not have any material impact to the financial results of the company.
• 1. Post implementation of Goods and Service Tax (GST) effective from I st July, 2017, revenue is reported net of GST as per Jnd AS-18/115. Revenue, however, is reported inclusive of excise duty for a part of the period ended 3 JS1 December, 2017. Had the previously repmted revenue been shown net of excise duty, comparative revenue of the company would have been as under:

1. Details offorex gain/(loss) are given below:

9.

Place: Hyderabad Date: 2"d February, 2019

Price Waterhouse Chartered Accountants LLP

The Board of Directors Divi's Laboratories Limited Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyclerabad- 500 032

• 1. We have reviewed the unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended December 31, 2018 which are included in the accompanying Statement of Standalone Unaudited financial results for the quarter and nine months ended December 31, 2018 (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been stamped by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
• 1. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
• 1. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
• 4· Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 ofthe Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP Firm Registration Number: FRN 012754N/N500016

V1

Sunit Kumar Basu Partner Membership Number: 55000

PIDce: O_UN o~E..uk D<~te: FeDruary 02, 2019

Price Waterhouse Chartered Accountants LLP, Plot No. 77/A, 8-2-624/A/1, 3rd Floor, Road No. 10, Banjara Hills Hyderabad- sao 034 T: +91 (40) 4424 6ooo, F: +91 (40) 4424 6300

Registered office and Head office· Sucheta Bhawan. 11A Vishnu Digambar Marg. New Delhi 110 002

Price Walerhollse (a Partnershtp Firm) converted into Price Waterhouse Chartered Accountants LLP ( a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) v.ii11 effect f1om July .25 2C~4 Post tis conversion to Price \11/aterhouse Chartered Accouni:anls LLP, its ICAl regislrat1on number IS 012754N/N500016 (lCAI registration nurnt:er before conversion 'N8S 012754N)

DIVI'S LABORATORIES LIMITED CIN No.L24110TG1990PLC011854 -- 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli Hyderabad- 500 032 Telangana, India Phone: 91-40-23786300 email: [email protected]

PRESS RELEASE dated 2"d February, 2019

Divi's Labs earns PATofRs.379 crores in Q3 ofFY19

Quarter ended 3Pt December, 2018

Divi's Laboratories has earned a Profit after Tax (PAT) ofRs. 379 crores on a total income of Rs. 1377 crores, on a stand-a lone basi , for the quarter ended 3 pt December, 20 I8. For the corresponding quarter of the last year, the company earned a PAT of Rs. 225 crores on a total income of Rs. I 055 crores.

During the quarter, there was a forex loss of Rs. 4I crores as against a forex loss of Rs. I6 crores during the corresponding quarter last year.

9-months ended 3Pt December, 2018

For the 9-month period ended 3 pt December, 20 I8, the company earned a total income of Rs. 3746 crores as compared to Rs. 2814 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs. 1423 crores as against a PBT of Rs. 823 crores for the previous period. PAT for the current 9-months is Rs. I 043 crores as against Rs. 608 crores.

Forex gain for the period came toRs. 38 crores as against Rs. 2 crores during the previous period.